US regulatory status: approved. Molecular target: Sodium-dependent dopamine transporter.
- Target
- Sodium-dependent dopamine transporter
- Mechanism
- Dopamine transporter releasing agent
pharma · Multiple Myeloma · Not applicable - Healthy volonteers · GPCR
Structure Therapeutics
Structure Therapeutics drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
601 Gateway Blvd, Suite 900, South San Francisco, California 94080, US HQ
2017 Founded
202 Employees
Public company Type
GPCR · NYSE Ticker
Company details
- Status
- Public
- HQ
- 601 Gateway Blvd, Suite 900, South San Francisco, California 94080, US
- Founded
- 2017
- Employees
- 202
- Programs
- 13
- Drugs
- 7
- Patents
- 93
Structure Therapeutics pipeline
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Structure Therapeutics drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Structure Therapeutics in public FDA and regional records.
-
Development asset linked to Structure Therapeutics in public FDA and regional records.
-
Development asset linked to Structure Therapeutics in public FDA and regional records.
-
Development asset linked to Structure Therapeutics in public FDA and regional records.
-
Development asset linked to Structure Therapeutics in public FDA and regional records.
-
Development asset linked to Structure Therapeutics in public FDA and regional records.